Clinical Trial Update: Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis

View source ↗

Summary

Pfizer is conducting a post-marketing surveillance study in Korea to monitor the safety of tofacitinib (Xeljanz) in pediatric patients with juvenile idiopathic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis
• Psoriatic Arthritis

Drugs mentioned

• XELJANZ (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Psoriatic Arthritis, Juvenile, Polyarticular Juvenile Idiopathic Arthritis | Status: RECRUITING